Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever

Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti‐interleukin‐1 drugs emerge as a therapeutic option for colchicine‐resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.

[1]  Ö. Varan,et al.  Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis , 2019, Modern rheumatology.

[2]  E. Çakıcı,et al.  Canakinumab treatment in children with familial Mediterranean fever: report from a single center , 2018, Rheumatology International.

[3]  T. Yıldırım,et al.  Canakinumab treatment in renal transplant recipients with familial Mediterranean fever , 2018, Journal of Nephrology.

[4]  K. Migita,et al.  Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis , 2017, Modern rheumatology.

[5]  P. Messiaen,et al.  Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature , 2016, Biologics : targets & therapy.

[6]  M. T. Terreri,et al.  Diretrizes de conduta e tratamento de síndromes febris periódicas associadas a febre familiar do Mediterrâneo , 2016 .

[7]  A. Gül,et al.  Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever , 2015, Arthritis Research & Therapy.

[8]  H. Ozdogan,et al.  The Emerging Treatments in Familial Mediterranean Fever , 2015 .

[9]  D. Solmaz,et al.  Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. , 2014, Rheumatology.

[10]  S. Sengul,et al.  Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra , 2014, Clinical kidney journal.

[11]  S. Baker,et al.  Summary Report , 2006 .

[12]  A. Bakkaloğlu,et al.  Familial Mediterranean Fever (FMF) in Turkey: Results of a Nationwide Multicenter Study , 2005, Medicine.

[13]  R. Gershoni-baruch,et al.  Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. , 2004, Seminars in arthritis and rheumatism.

[14]  T. Ecder,et al.  Renal transplantation in amyloidosis secondary to familial Mediterranean fever. , 2001, Transplantation proceedings.

[15]  D. Zemer,et al.  Criteria for the diagnosis of familial Mediterranean fever. , 1997, Arthritis and rheumatism.